November 14, 2023 02:57 AM ESTUpdated 06:06 AM
People
R&D

The­seus Phar­ma­ceu­ti­cals lays off most work­ers and seeks 's­trate­gic al­ter­na­tives' af­ter can­cer pipeline fail­ure

Kyle LaHucik

Senior Reporter

The­seus Phar­ma­ceu­ti­cals said af­ter Mon­day’s clos­ing bell that it will let go of 72% of its work­force, or about 26 peo­ple, and will seek “strate­gic …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

Among phar­ma CEOs, the IRA now and the IRA lat­er get very dif­fer­ent re­ac­tions

Bris­tol My­ers restarts ra­dio­phar­ma­ceu­ti­cal Phase 3 tri­al, but de­lays read­out by one year

Up­dat­ed: With cost-cut­ting un­der­way, Bris­tol My­ers rais­es guid­ance, touts Phase 3 win and scraps an­oth­er

An­drew Left, short sell­er who cam­paigned against Valeant, is ac­cused of fraud by SEC

Eu­ro­pean drug reg­u­la­tor re­jects Alzheimer's drug Leqem­bi, cit­ing safe­ty con­cerns

sponsored

Crit­i­cal Junc­tures in Gene Ther­a­py Clin­i­cal Ma­te­r­i­al Man­u­fac­tur­ing: Where Do I Start? And Will It Work?

A service from the Financial Times